Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Sanofi-Aventis S.A. ADR (NQ: SNY ) 55.05 -0.17 (-0.31%) Streaming Delayed Price Updated: 10:06 AM EDT, Aug 22, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Sanofi-Aventis S.A. ADR < Previous 1 2 ... 23 24 25 26 27 28 29 30 Next > CHMP Backs Sanofi-Regeneron's Dupixent For Asthma Patients Aged 6 - 11 Years With Type 2 Inflammation January 31, 2022 The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has adopted a posi Via Benzinga Regeneron, Sanofi Withdraw FDA Application For Libtayo's Expanded Use January 28, 2022 Regeneron Pharmaceuticals Inc (NASDAQ: REGN) and its partner Sanofi SA (NASDAQ: SNY) have Via Benzinga The Daily Biotech Pulse: Biogen Liquidates Out Of Biosimilar JV, Provention Bio Plots Diabetes Drug Resubmission, Merck Finds COVID Pill Effective Against Omicron January 28, 2022 Here's a roundup of top developments in the biotech space over the last 24 hours: Via Benzinga Billions Flowing into Cancer Immunotherapy as Market Responds to Impressive Market Potential January 24, 2022 FN Media Group Presents USA News Group News Commentary Vancouver, BC – January 24, 2022 – USA News Group – Within the grand battle against cancer, the use of immunotherapy continues to grow at... Via FinancialNewsMedia Why Jim Cramer Like NextEra Energy And Lincoln Electric? January 21, 2022 On CNBC’s "Mad Money Lightning Round," Jim Cramer said NextEra Energy, Inc. (NYSE: Via Benzinga Second Dupixent Phase 3 Trial Confirms Significant Improvements In Inflammatory Skin Disease January 19, 2022 Sanofi SA (NASDAQ: SNY) and Regeneron Pharmaceuticals Inc (NASDAQ: REGN) have announced data from the second Phase 3 trial of Dupixent (dupilumab) in... Via Benzinga Connect Biopharma's Latest Dermatitis Drug Update Fails to Pump Up Shares January 13, 2022 Key takeaways: Loss-making Connect Biopharma says Phase 3 clinical trials of its CBP-201 drug for atopic dermatitis will begin in second half of this year Connect Biopharma... Via Benzinga Acasti Pharma: Bouncing Back With a New Drug Pipeline January 04, 2022 Picture credit: Louis Reed on Unsplash The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial... Via Benzinga Global Alzheimer’s Disease Therapeutics Market Projected To Generate Revenue Of $9.97 Billion By 2028 January 04, 2022 Palm Beach, FL –January 4, 2022 – FinancialNewsMedia.com News Commentary – Alzheimer’s disease is a degenerative, progressive ailment that attacks the brain’s nerve cells, resulting in memory loss,... Via FinancialNewsMedia Exposures COVID-19 Sanofi Expects Q4 FY21 Vaccine Sales Lower Than Year-Ago, Positive Currency Impact January 04, 2022 Sanofi SA (NASDAQ: SNY) says the preliminary estimate of currency impact on Q4 sales and business EPS is approximately +1.5% and +2.5%. Also, the Company expects... Via Benzinga Attention Biotech Investors: Mark Your Calendar For January PDUFA Dates December 31, 2021 Regulatory decisions by the U.S. Food and Drug Administration in December turned out to be mostly positive. Among the treatment options that were greenlighted in the month were... Via Benzinga 3 Cathie Wood Stocks To Buy On The Dip December 25, 2021 Institutional investor Cathie Wood gained popularity after her ETFs generated big gains last year. Wood asserted recently that her stocks are poised for long-term gains. Hence, we think investing in... Via Talk Markets Plague Year Reversal December 21, 2021 Just in time for Christmas, the market decided to go up today pretty much across the board. Via Talk Markets The Daily Biotech Pulse: Aldeyra Sinks On Dry Eye Disease Readout, Sanofi Goes Shopping, Regulatory Setback For Aquestive, Aridis Touts Pan-Coronavirus Antibody Cocktail December 21, 2021 Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus CytomX Mid-Phase Study Of ADC In Lung And Head & Neck Cancer Patients... Via Benzinga Sanofi Agrees To Buy US-Based Amunix Pharma For $1B Upfront December 21, 2021 Sanofi SA (NASDAQ: SNY) will buy an immuno-oncology company, Amunix Pharmaceuticals Inc, for an upfront payment of about $1 billion. Sanofi will also pay Amunix up... Via Benzinga GlaxoSmithKline: Investing In Vaccines December 19, 2021 GlaxoSmithKline, based in London, is a global healthcare company engaged in the discovery, development, manufacture, and marketing of pharmaceutical and consumer healthcare products. Let's take a look... Via Talk Markets Raising Rates December 16, 2021 The Bank of England raised its interest rate to 0.25%, setting a pattern for other countries. Via Talk Markets How Will Moderna Stock Weather Omicron? — And Other Questions Clouding 2022 December 16, 2021 Analysts call for a sales and earnings decline in 2022. Can Moderna stave it off? Via Investor's Business Daily Sanofi, Glaxo's COVID-19 Vaccine Candidate Works As Booster, But Data Readout Pushed Back December 15, 2021 Sanofi SA (NASDAQ: SNY) and GlaxoSmithKline Plc (NYSE: GSK) expect data from late-stage trials of its COVID-19 booster dose in Q1 2022, instead of this year.... Via Benzinga The Daily Biotech Pulse: Lilly Raises Guidance, Medtronic Gets FDA Warning Letter, Decision Day For Calliditas, Genenta IPO December 15, 2021 Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Vir Biotech Says COVID-19 Antibody Treatment Effective Against Omicron... Via Benzinga 3 Stocks That Can Make You Rich in Just a Few Years December 14, 2021 Investing in the most popular stocks on the Street won't make investors rich in a few years. To accomplish that goal, a contrarian spirit is needed. Via InvestorPlace Sanofi Reveals Late-Stage Data For Fitusiran In Hemophilia Patients December 14, 2021 Sanofi SA (NASDAQ: SNY) presented data from two Phase 3 studies of fitusiran for the prophylactic treatment with hemophilia A or B, with or without inhibitors.... Via Benzinga Are Cannabinoids the Next Frontier of Pharmaceuticals? This Company Thinks So and Wants to Lead the Pack December 14, 2021 Photo by Michael Longmire on... Via Benzinga Comparing Data: Sanofi Vs. Johnson & Johnson Multiple Myeloma Therapies In Newly Diagnosed Patients December 13, 2021 Sanofi SA (NASDAQ: SNY) and Johnson & Johnson (NYSE: JNJ) posted new data from their myeloma therapies, Sarclisa and Darzalex, respectively. Data were shared at... Via Benzinga Inflation Surge December 10, 2021 Today the market failed to brush off inflation fears as it had done later on Thursday as inflation is at a 4 decade high. Via Talk Markets Moderna Stock Dives As Sanofi-Rivaling Flu Shot Underwhelms In First Test December 10, 2021 The results were generally in line with an older flu shot from Sanofi. Via Investor's Business Daily Moderna Posts Data From Early mRNA Flu Vaccine Study, Pivotal Trial On Its Way December 10, 2021 Moderna Inc (NASDAQ: MRNA) says that it's on its way to having two mRNA vaccines against different seasonal flu viruses. The Company released the first early data... Via Benzinga Regeneron: Surfing on Covid, With More Under the Surface December 02, 2021 Regeneron has a method for finding blockbuster drugs, like the Covid drug that powered 2021 REGN stock results, but there's even more to come. Via InvestorPlace Exposures COVID-19 Is High Pressure Good for Drug Development? December 02, 2021 Picture credit: National Cancer Institute The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a... Via Benzinga Britain Agrees To New Deals For 114M Additional Moderna, Pfizer/BioNTech COVID-19 Vaccine Doses December 02, 2021 The British government has agreed on deals to buy 114 million more Pfizer Inc (NYSE: PFE) / BioNTech SE (NASDAQ: BNTX) and Moderna Inc (... Via Benzinga Exposures COVID-19 < Previous 1 2 ... 23 24 25 26 27 28 29 30 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.